$400M Oberland Capital Bet on MeiraGTx Fuels Gene Therapy Push
Event summary
- MeiraGTx secures $400M investment from Oberland Capital, including $375M in non-dilutive royalty funding and $25M in equity.
- $135M initial tranche includes $125M for low single-digit royalties on AAV2-hAQP1, bota-vec, and AAV-AIPL1.
- Additional $150M tied to 2027/2028 regulatory milestones for bota-vec and AAV2-hAQP1.
- $100M reserved for new products or business development under mutual agreement.
The big picture
Oberland Capital's $400M bet underscores confidence in MeiraGTx's pipeline, particularly bota-vec and AAV2-hAQP1, targeting unmet needs in XLRP and radiation-induced xerostomia. The non-dilutive structure preserves equity flexibility while funding commercialization of three near-term candidates. This aligns with broader biotech trends favoring milestone-based financing for late-stage gene therapies.
What we're watching
- Regulatory Momentum
- Whether MeiraGTx can deliver on 2027/2028 approval timelines for bota-vec and AAV2-hAQP1 to unlock remaining tranches.
- Commercialization Scale
- How $400M investment positions MeiraGTx against competitors in first-to-market gene therapies for XLRP and radiation-induced xerostomia.
- Capital Flexibility
- The pace at which MeiraGTx deploys the $100M reserved for new products or business development.
Related topics